Skip to main content

Clear Cell Renal Cell Cancer Clinical Trials

Review the clear cell renal cell cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 53

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) after Surgery to Remove all Known Sites of Kidney Cancer
Status: Active
Location: 396 locations
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Status: Active
Location: 17 locations
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Status: Active
Location: 14 locations
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Status: Active
Location: 17 locations
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Status: Active
Location: 11 locations
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Status: Active
Location: 12 locations
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Status: Active
Location: 9 locations
Cemiplimab and Fianlimab before Surgery for the Treatment of Patients with Locally Advanced Kidney Cancer Undergoing Nephrectomy
Status: Active
Location: 7 locations
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Status: Active
Location: 8 locations
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Status: Active
Location: 7 locations
Alternate Cabozantinib Dosing Schedule Alone and in Combination with Nivolumab for the Treatment of Metastatic Kidney Cancer and Neuroendocrine Tumors
Status: Active
Location: 5 locations
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Status: Active
Location: 5 locations
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Status: Active
Location: 5 locations
Ceralasertib with or without Olaparib or Durvalumab in Treating Patients with Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 4 locations
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Status: Active
Location: 6 locations
Neoadjuvant Pembrolizumab and Axitinib for Treatment of Patients with Kidney Cell Carcinoma and Associated Inferior Vena Cava Tumor Thrombus, NEOPAX Trial
Status: Active
Location: 3 locations
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Status: Active
Location: 3 locations
XL092 with or without Nivolumab for the Treatment of Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status: Active
Location: 2 locations
177Lu-PSMA-617 for the Treatment of Advanced Clear Cell Renal Cell Carcinoma, LASER Trial
Status: Active
Location: 2 locations
Sasanlimab, Palbociclib and Axitinib for the Treatment of Unresectable Advanced or Metastatic Renal Cell Carcinoma, The SPARCC Trial
Status: Active
Location: 2 locations
Cytokine Induced Memory-Like Natural Killer Cells in Combination with Aldesleukin for the Treatment of Locally Advanced or Metastatic Renal Cell Cancer or Urothelial Cancer
Status: Active
Location: 2 locations
Pembrolizumab after Radiation Therapy for the Treatment of Patients with Oligometastatic Renal Cell Cancer, ASTROs Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Molecular Residual Disease-Guided Treatment of Renal Cell Carcinoma, MRD GATE RCC Trial
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
A Dendritic Cell Vaccine in Combination with Cabozantinib for Altering the Immune System in Patients with Localized Clear Cell Renal Cell Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Belzutifan or Pembrolizumab Alone versus in Combination for Neoadjuvant Treatment of Clear Cell Renal Cell Cancer, BLAZE Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas